SZLSF (StageZero Life Sciences) OCF Yield %: -23.17 (As of Jul. 01, 2026)


SZLSF StageZero Life Sciences Ltd SZLSF
10 GF Score
Price $0.01
View Full Analysis

What is StageZero Life Sciences OCF Yield %?

StageZero Life Sciences SZLSF 10 OCF Yield % is -23.17 as of Jul. 01, 2026. GuruFocus rates SZLSF with a GF Score™ of 10/100.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, StageZero Life Sciences's Trailing 12-Month Cash Flow from Operations is $-0.15 Mil, and Market Cap is $0.63 Mil. Therefore, StageZero Life Sciences's OCF Yield % for today is -23.17%.

The historical rank and industry rank for StageZero Life Sciences's OCF Yield % or its related term are showing as below:

SZLSF' s OCF Yield % Range Over the Past 10 Years
Min: -235.48   Med: 0   Max: -23.17
Current: -23.17


During the past 13 years, the highest OCF Yield % of StageZero Life Sciences was -23.17%. The lowest was -235.48%. And the median was %.

SZLSF's OCF Yield % is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.99 vs SZLSF: -23.17

StageZero Life Sciences's OCF Margin % for the quarter that ended in Sep. 2024 was %.


StageZero Life Sciences OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


StageZero Life Sciences OCF Yield % Related Terms


StageZero Life Sciences OCF Yield % Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences OCF Yield % Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -59.21 -59.12 -8.63 -42.86 -75.53

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 3.87 -8.59 -136.00 0.81

SZLSF vs IDTA, TTOO, NSTM: OCF Yield % Comparison

For the Diagnostics & Research subindustry, StageZero Life Sciences's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences OCF Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's OCF Yield % distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's OCF Yield % falls into.


SZLSF
10GF Score
StageZero Life Sciences Ltd SZLSF
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

StageZero Life Sciences OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

StageZero Life Sciences's OCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-3.529 / 4.6720995
=-75.53%

StageZero Life Sciences's annualized OCF Yield % for the quarter that ended in Sep. 2024 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=0.01 * 4 / 4.94132
=0.81%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -23.17 mean?
StageZero Life Sciences (SZLSF) has a OCF Yield % of -23.17 as of Jul. 01, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on StageZero Life Sciences and its competitors.
Is StageZero Life Sciences' OCF Yield % too high?
StageZero Life Sciences' current OCF Yield % is -23.17. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does StageZero Life Sciences' OCF Yield % compare to IDTA and TTOO?
StageZero Life Sciences' OCF Yield % of -23.17 can be compared against companies in the Medical Diagnostics & Research industry. The industry median OCF Yield % is 0.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 0.99, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on StageZero Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StageZero Life Sciences's current OCF Yield % is -23.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StageZero Life Sciences stock overvalued right now?
StageZero Life Sciences (SZLSF) has a current OCF Yield % of -23.17. The current OCF Yield % is -23.17. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current OCF Yield % is -23.17 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.
10GF Score

Get the complete analysis for SZLSF

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price